Главная страницаLBank Stocks
Nutriband Inc
Nutriband Inc

Nutriband Inc (NTRB)

24HВысокий$4.7524HНизкий$3.87
$4.67
+0.20%

Последнее обновление: 2026-08-25 10:47:38

Симуляция графика K-линий, фактические данные указаны на торговой странице

Ключевые данные

Открытие вчера
$3.88
Пред. закрытие
$4.67
Вчерашний диапазон
$3.87 - $4.75
Диапазон 52 нед.
$2.80 - $8.63
Объем торговли
62.347K
МС
$62.117M
P/E
--
EPS
$-2.80

Обзор компании

NASDAQ

Nutriband Inc. develops a portfolio of transdermal pharmaceuticals. The company is headquartered in Orlando, Florida.

СекторHEALTHCARE
ОтрасльBIOTECHNOLOGY
Штаб-квартира121 SOUTH ORANGE AVENUE, ORLANDO, FL, UNITED STATES, 32801
СтранаUSA
Дата листинга2017-06-20
Конец финансового года2026-04-30
Акции в обращении12.156M
Код CIK1676047

Финансовые показатели

Индикатор2026-04-302026-01-312025-10-312025-07-31
Доход$433.399K$400.709K$346.058K$622.452K
Операционные расходы$236.598K$311.768K$277.553K$465.571K
Чистая прибыль-$1.242M-$968.059K-$3.872M-$2M
Чистая рентабельность-286.6%-241.6%-1119.0%-321.4%
Прибыль на акцию$-0.10$-0.08$-0.32$-0.18
EBITDA-$1.203M-$926.846K-$3.824M-$1.937M
Эффективная налоговая ставка--------

Часто задаваемые вопросы

NTRB specializes in biotechnology, focusing on innovative solutions within the life sciences sector. The company operates in the biotechnology industry, leveraging cutting-edge research and advanced technology to address critical health challenges.
NTRB’s primary revenue drivers stem from its development and commercialization of biotechnological products and solutions. These often include therapies, medical technologies, or research innovations aimed at addressing unmet medical needs within its target markets.
NTRB faces competition from other biotechnology firms focused on similar therapeutic areas. Key competitors may include both established industry leaders and emerging companies that specialize in innovative treatments and life sciences advancements.
Opportunities include the potential for significant growth driven by innovation and demand for new health solutions. Risks include the inherent uncertainties of biotechnology development, including regulatory hurdles, competition, and the high costs of research and commercialization.
No, NTRB does not currently pay dividends. As a biotechnology company, it likely reinvests earnings into research and development to drive long-term growth and innovation, which is common in this sector.
NTRB’s valuation can be assessed based on factors like its market capitalization and potential growth compared to its biotechnology peers. Investors should conduct detailed research, considering metrics such as revenue prospects and innovation pipelines to make informed comparisons.
The biotechnology industry has unique risks, including high research and development costs, regulatory uncertainty, clinical trial outcomes, and competitive pressures. These factors can significantly impact companies like NTRB and their financial outcomes.
Investors should consider NTRB’s focus on innovation and its position within the biotechnology industry. Growth potential may depend on its ability to develop successful products and navigate industry risks, but outcomes are inherently uncertain in this competitive sector.
Предупреждение о рисках
  1. 1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
  2. 2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
  3. 3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.